Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (Rinvoq®▼), ABROCITINIB tablets (Cibinqo®▼), or TRALOKINUMAB injection (Adtralza®▼) for treating moderate to severe atopic dermatitis

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 30 - Sep - 2022
Body System:
Red
UPADACITINIB prolonged-release tablets (Rinvoq®▼), ABROCITINIB tablets (Cibinqo®▼), or TRALOKINUMAB injection (Adtralza®▼) for treating moderate to severe atopic dermatitis

The Pan Mersey Area Prescribing Committee recommends the prescribing of ABROCITINIB tablets (Cibinqo®▼), TRALOKINUMAB injection (Adtralza®▼) or UPADACITINIB prolonged-release tablets (Rinvoq®▼), by specialists only, for treating moderate to severe atopic dermatitis in accordance with NICE TA814.

NHS Cheshire and Merseyside APPROVED